# A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors

> **NCT06235983** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 12 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** LY3537982

## Key facts

- **NCT ID:** NCT06235983
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-29
- **Primary completion:** 2026-04
- **Final completion:** 2027-04
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06235983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06235983, "A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06235983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*